tetano
Editor, Senior Moderator
Front Immunol
. 2022 Jan 21;12:821538.
doi: 10.3389/fimmu.2021.821538. eCollection 2021.
mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
Yingqi Jin[SUP] 1 [/SUP], Chen Hou[SUP] 1 [/SUP], Yonghao Li[SUP] 1 [/SUP], Kang Zheng[SUP] 2 [/SUP], Chuan Wang[SUP] 1 3 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high infectivity, pathogenicity, and variability, is a global pandemic that severely affected public health and the world economy. The development of safe and effective vaccines is crucial to the prevention and control of an epidemic. As an emerging technology, mRNA vaccine is widely used for infectious disease prevention and control and has significant safety, efficacy, and high production. It has received support and funding from many pharmaceutical enterprises and becomes one of the main technologies for preventing COVID-19. This review introduces the current status of SARS-CoV-2 vaccines, specifically mRNA vaccines, focusing on the challenges of developing mRNA vaccines against SARS-CoV-2, and discusses the relevant strategies.
Keywords: COVID-19; SARS-CoV-2; challenges; mRNA vaccine; strategies.
. 2022 Jan 21;12:821538.
doi: 10.3389/fimmu.2021.821538. eCollection 2021.
mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
Yingqi Jin[SUP] 1 [/SUP], Chen Hou[SUP] 1 [/SUP], Yonghao Li[SUP] 1 [/SUP], Kang Zheng[SUP] 2 [/SUP], Chuan Wang[SUP] 1 3 [/SUP]
Affiliations
- PMID: 35126377
- PMCID: PMC8813741
- DOI: 10.3389/fimmu.2021.821538
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high infectivity, pathogenicity, and variability, is a global pandemic that severely affected public health and the world economy. The development of safe and effective vaccines is crucial to the prevention and control of an epidemic. As an emerging technology, mRNA vaccine is widely used for infectious disease prevention and control and has significant safety, efficacy, and high production. It has received support and funding from many pharmaceutical enterprises and becomes one of the main technologies for preventing COVID-19. This review introduces the current status of SARS-CoV-2 vaccines, specifically mRNA vaccines, focusing on the challenges of developing mRNA vaccines against SARS-CoV-2, and discusses the relevant strategies.
Keywords: COVID-19; SARS-CoV-2; challenges; mRNA vaccine; strategies.